Table 3. GSTT1, GSTP1, GSTO1, GSTO2, GSTM1 and GSTA1 polymorphisms as the predictors for overall mortality among 101 patients with muscle invasive TCC after 5 yrs of follow-up by the Cox proportional hazards regression.

Model 1a		Model 2b
HR (95% CI)	P-value	HR (95% CI)	P-value
Risk of overall mortality comparing GSTT1 active to GSTT1 null genotype
2.032 (0.989–4.173)	0.054	2.471 (1.101–5.545)	0.028
Risk of overall mortality comparing GSTP1*Ile carriers to GSTP1*Val homozygotes
2.102 (0.128–5.336)	0.118	2.071 (0.723–5.935)	0.175
Risk of overall mortality comparing GSTO1*Asp homozygotes to GSTO1*Ala carriers
1.962 (0.812–4.744)	0.134	2.941 (1.164–7.430)	0.022
Risk of overall mortality comparing GSTO2*Asp homozygotes to GST02*Asn carriers
2.870 (1.355–6.076)	0.006	3.967 (1.760–8.939)	0.001
Risk of overall mortality comparing GSTM1 null genotype to GSTM1 active
1.062 (0.609–1.852)	0.833	1.128 (0.620–2.052)	0.694
Risk of overall mortality comparing GSTA1*B homozygotes to GSTA1*A carriers
1.190 (0.671–2.112)	0.552	1.387 (0.615–3.127)	0.430

Abbreviations: CI, Confidence Interval; HR, Hazard Ratio.

^aAdjusted for age and gender.

^bAdjusted for the covariates in Model 1 plus an additional adjustment for grade.